{"id":44432,"date":"2022-05-27T15:01:13","date_gmt":"2022-05-27T13:01:13","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\/"},"modified":"2022-05-27T15:01:13","modified_gmt":"2022-05-27T13:01:13","slug":"lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\/","title":{"rendered":"LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting"},"content":{"rendered":"
\n

GUANGZHOU, China–(BUSINESS WIRE)–LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that preliminary results of Catumaxomab for advanced Gastric Cancer (GC) with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.\n<\/p>\n

<\/a><\/p>\n

\nAbstract Number\uff1a<\/b>e16102
\n
Abstract Title\uff1a<\/b>Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis.<\/a>\n<\/p>\n

\nThe abstract is about the cohort A, stage I of the ongoing global phase \u2162 trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis (clinicaltrials.gov: NCT04222114). Worldwide, GC is one of the most common cancers, contributing to more than 1 million cases per year and 5.6% of all cancer diagnoses [1]<\/sup>. Approximately 50% of the advanced GC patients will develop peritoneal metastasis after radical resection, along with malignant ascites in most cases. Furthermore, peritoneal metastasis is associated with poor prognosis and quality of life compared with metastasis to other organs [2]<\/sup>. Peritoneal metastasis is treated with systemic therapies. The estimated survival period for the patients who fail to respond to third-line therapy is limited to only 2.3-2.4 months according to multiple RCTs.\n<\/p>\n

\nIn our study, 9 GC patients with peritoneal metastasis (33% had failed third-line therapy) were treated with Catumaxomab, the median overall survival was 3.4 months, with remarkable ascites regression. Catumaxomab as an T cell engaging immunotherapy has showed promising early efficacy signals.\n<\/p>\n

\nAbout Catumaxomab
\n
<\/b>Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. It is a bispecific antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell–and CD3 on the T cell, recruits immune accessory cells through Fc\u03b3R binding at the same time. Catumaxomab kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models. Currently, Catumaxomab is being evaluated in clinical trials for both advanced gastric cancer (NCT04222114) and non-muscle invasive bladder cancer (NCT04799847).\n<\/p>\n

\nAbout LintonPharm
\n
<\/b>LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm has developed multiple bispecific antibody platforms with a great potential of refined safety and efficacy profiles, long-lasting vaccinal effects and CMC efficiency. The current pipeline includes several treatments in development for blood cancer and solid tumors. For more information, please visit www.lintonpharm.com<\/a>\n<\/p>\n

\nReference<\/b>\n<\/p>\n

\n1. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https:\/\/gco.iarc.fr\/<\/a>
2. Jennifer L.L. & Travis E.G. Optimizing outcomes for patients with gastric cancer peritoneal carcinomatosis. World J Gastrointest Oncol 2018 October 15; 10(10): 282-289.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contacts:<\/b>
Mia He
\n
LintonPharm
\n
jingyi.he@lintonpharm.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

GUANGZHOU, China–(BUSINESS WIRE)–LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that preliminary results of Catumaxomab for advanced Gastric Cancer (GC) with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract Number\uff1ae16102 Abstract Title\uff1aGlobal multi-center … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44432","6":"format-standard","7":"category-industry"},"yoast_head":"\nLintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"GUANGZHOU, China–(BUSINESS WIRE)–LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that preliminary results of Catumaxomab for advanced Gastric Cancer (GC) with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract Number\uff1ae16102 Abstract Title\uff1aGlobal multi-center ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-27T13:01:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220527005174\/en\/1469325\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting\",\"datePublished\":\"2022-05-27T13:01:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\\\/\"},\"wordCount\":485,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220527005174\\\/en\\\/1469325\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\\\/\",\"name\":\"LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220527005174\\\/en\\\/1469325\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-05-27T13:01:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220527005174\\\/en\\\/1469325\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220527005174\\\/en\\\/1469325\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting - Pharma Trend","og_description":"GUANGZHOU, China–(BUSINESS WIRE)–LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that preliminary results of Catumaxomab for advanced Gastric Cancer (GC) with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract Number\uff1ae16102 Abstract Title\uff1aGlobal multi-center ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-27T13:01:13+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220527005174\/en\/1469325\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting","datePublished":"2022-05-27T13:01:13+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\/"},"wordCount":485,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220527005174\/en\/1469325\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\/","name":"LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220527005174\/en\/1469325\/21\/logo.jpg","datePublished":"2022-05-27T13:01:13+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220527005174\/en\/1469325\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220527005174\/en\/1469325\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/lintonpharm-to-release-data-on-catumaxomab-for-advanced-gastric-cancer-with-peritoneal-metastasis-at-2022-asco-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44432","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44432"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44432\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44432"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44432"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44432"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}